Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.5K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.5K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

5.2K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
5.2K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.3K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.3K
Cells of the Innate Immune Response01:28

Cells of the Innate Immune Response

6.9K
The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
6.9K
Overview of Cell Death01:30

Overview of Cell Death

8.1K
Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
8.1K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

77.1K
Overview
77.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autophagy Modulates Immunogenic Cell Death in Cancer.

Cancers·2026
Same author

Ambroxol induces myeloma cell death by inhibiting autophagy.

Blood neoplasia·2025
Same author

Immunomodulatory Effect of Proteasome Inhibitors via the Induction of Immunogenic Cell Death in Myeloma Cells.

Pharmaceuticals (Basel, Switzerland)·2023
Same author

GTN057, a komaroviquinone derivative, induced myeloma cells' death in vivo and inhibited c-MET tyrosine kinase.

Cancer medicine·2023
Same author

[PAX5-positive plasma cell leukemia presenting as lymphocytosis].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2022
Same author

Integrin β5 and β7 expression in lenalidomide-resistant multiple myeloma cells.

International journal of hematology·2022

Related Experiment Video

Updated: Oct 25, 2025

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.8K

[Immunogenic cell death in hematological malignancies].

Maiko Matsushita1

  • 1Division of Clinical Physiology and Therapeutics, Keio University Faculty of Pharmacy.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|August 5, 2021
PubMed
Summary

Cytotoxic drugs can trigger immunogenic cell death (ICD) in cancer cells, enhancing long-term immune memory and patient survival. This discovery extends to hematological malignancies and offers new combination therapy strategies.

Keywords:
Damage-associated molecular patternsImmunogenic cell deathLeukemiaMyeloma

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.2K
Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
09:57

Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells

Published on: January 29, 2019

22.9K

Related Experiment Videos

Last Updated: Oct 25, 2025

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.8K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.2K
Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
09:57

Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells

Published on: January 29, 2019

22.9K

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Anticancer therapies, particularly cytotoxic drugs, were historically viewed as immunosuppressive.
  • Emerging evidence indicates these therapies can induce immunogenic cell death (ICD) in cancer cells.

Purpose of the Study:

  • To explore the role of immunogenic cell death (ICD) in cancer therapy.
  • To highlight the potential of ICD inducers for enhancing anti-cancer immunity and patient outcomes.
  • To investigate the applicability of ICD in hematological malignancies.

Main Methods:

  • Review of existing studies on cytotoxic drugs, tumor-lytic viruses, and radiation therapy.
  • Analysis of damage-associated molecular patterns (DAMPs) emission from cancer cells.
  • Examination of ICD induction in both solid tumors and hematological malignancies.

Main Results:

  • Anticancer therapies can induce ICD, leading to the emission of DAMPs.
  • ICD activates acquired immunity and establishes long-term immune memory.
  • ICD has been observed in hematological malignancies, not just solid tumors.

Conclusions:

  • ICD is a crucial phenomenon in cancer therapy, potentially prolonging patient survival.
  • Combining ICD inducers with other immunotherapies, like CAR-T-cell therapy, is a promising strategy.
  • Future treatment strategies should prioritize drugs with the ability to evoke ICD.